Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Mona Arab-Alameddine"'
Autor:
M. Guidi, Mona Arab-Alameddine, Margalida Rotger, Manel Aouri, Amalio Telenti, Laurent A. Decosterd, Thierry Buclin, Chantal Csajka
Publikováno v:
CHIMIA, Vol 66, Iss 5 (2012)
Pharmacokinetic variability in drug levels represent for some drugs a major determinant of treatment success, since sub-therapeutic concentrations might lead to toxic reactions, treatment discontinuation or inefficacy. This is true for most antiretro
Externí odkaz:
https://doaj.org/article/3a79cf769bba41729437f48593d67ad7
Autor:
Clarisse Chavanne, Navita L. Mallalieu, Valerie Cosson, Elena Guerini, Mona Arab‐Alameddine, Michael Derks, Franziska Schaedeli-Stark
Publikováno v:
Clinical and Translational Science. 11:523-531
Dizziness, the most frequently observed adverse event in patients with major depressive disorder, was observed with basimglurant, a selective, orally active metabotropic glutamate receptor subtype 5 negative allosteric modulator. The potential relati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ec87d16325e1a56fa723676ecd5253ef
https://doi.org/10.1111/cts.12566
https://doi.org/10.1111/cts.12566
Autor:
Rubin, Lubomirov, Mona, Arab-Alameddine, Margalida, Rotger, Aurélie, Fayet-Mello, Raquel, Martinez, Monia, Guidi, Julia, di Iulio, Matthias, Cavassini, Huldrych F, Günthard, Hansjakob, Furrer, Catia, Marzolini, Enos, Bernasconi, Alexandra, Calmy, Thierry, Buclin, Laurent A, Decosterd, Chantal, Csajka, Amalio, Telenti, S, Yerly
Publikováno v:
Pharmacogenetics and Genomics, Vol. 23, No 1 (2013) pp. 9-18
OBJECTIVES: Etravirine (ETV) is metabolized by cytochrome P450 (CYP) 3A, 2C9, and 2C19. Metabolites are glucuronidated by uridine diphosphate glucuronosyltransferases (UGT). To identify the potential impact of genetic and non-genetic factors involved
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a251c4bdf7d3de477c66e4e5bfd72ede
https://www.zora.uzh.ch/id/eprint/68368/
https://www.zora.uzh.ch/id/eprint/68368/
Antiretroviral drug toxicity in relation to pharmacokinetics, metabolic profile and pharmacogenetics
Publikováno v:
Expert opinion on drug metabolism & toxicology
Europe PubMed Central
Europe PubMed Central
Introduction: Besides therapeutic effectiveness drug tolerability is a key issue for treatments that must be taken indefinitely. Given the high prevalence of toxicity in HIV therapy the factors implicated in drug induced morbidities should be identif
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dd2e5ac943f04f9caf3bdfc447dcee1f
https://pubmed.ncbi.nlm.nih.gov/21500966
https://pubmed.ncbi.nlm.nih.gov/21500966
Autor:
Thierry Buclin, Manel Aouri, Chantal Csajka, Amalio Telenti, Mona Arab-Alameddine, Margalida Rotger, Laurent A. Decosterd, Monia Guidi
Publikováno v:
CHIMIA, Vol 66, Iss 5 (2012)
Pharmacokinetic variability in drug levels represent for some drugs a major determinant of treatment success, since sub-therapeutic concentrations might lead to toxic reactions, treatment discontinuation or inefficacy. This is true for most antiretro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9727d2dcaa5a02c631db0da663a77988
https://doi.org/10.2533/chimia.2012.291
https://doi.org/10.2533/chimia.2012.291